lytgobi
taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - medicamente antineoplazice - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
cabometyx 20 mg
patheon france - franta - cabozantinibum - compr. film. - 20mg - alte antineoplazice inhibitori de protein-kinaza
cabometyx 40 mg
patheon france - franta - cabozantinibum - compr. film. - 40mg - alte antineoplazice inhibitori de protein-kinaza
cabometyx 60 mg
patheon france - franta - cabozantinibum - compr. film. - 60mg - alte antineoplazice inhibitori de protein-kinaza
imbruvica 140 mg
janssen pharmaceutica nv - belgia - ibrutinibum - caps. - 140mg - alte antineoplazice inhibitori de protein-kinaza
imbruvica 140 mg
janssen cilag spa - italia - ibrutinibum - compr. film. - 140mg - alte antineoplazice inhibitori de protein-kinaza
imbruvica 280 mg
janssen cilag spa - italia - ibrutinibum - compr. film. - 280mg - alte antineoplazice inhibitori de protein-kinaza
imbruvica 420 mg
janssen cilag spa - italia - ibrutinibum - compr. film. - 420mg - alte antineoplazice inhibitori de protein-kinaza
imbruvica 560 mg
janssen cilag spa - italia - ibrutinibum - compr. film. - 560mg - alte antineoplazice inhibitori de protein-kinaza
mektovi 15 mg
pierre fabre mÉdicament production - franta - binimetinibum - compr. film. - 15mg - alte antineoplazice inhibitori de protein-kinaza